Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2025
Double-Masked Controlled Trial of H-1337 as a Treatment for Glaucoma and Ocular Hypertension.
СтатьяРандомизированное исследованиеКлиническое исследование II фазыМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shettle Lee, Mulaney Jay, Williams Robert D, Beck Jennifer, Stewart Jeanette A, Novack Gary D
Аннотация
PURPOSE: Extend Phase 2A study to evaluate additional concentrations of H-1337 and dosing frequencies, and to compare them with a positive control.
DESIGN: Phase 2B, randomized, double-masked, active-controlled, dose-response study of 28 days of four treatments: H-1337 0.6% b.i.d., 1.0% b.i.d., or 1.0% q.d. (1.0% in the morning with H-1337 vehicle in the evening), and timolol maleate 0.5% b.i.d.
PARTICIPANTS: Two hundred one subjects with open-angle glaucoma or ocular hypertension at eight private practice sites in the United States.
METHODS: Diurnal intraocular pressure (IOP) over 28 days of dosing.
MAIN OUTCOME MEASURES: Non-inferiority to timolol in change from baseline in IOP at Day 1 and Day 28.
RESULTS: Mean reduction in IOP was 4-7 mmHg for the H-1337 groups and 5-8 mmHg for the timolol group. Non-inferiority to timolol for H-1337 1.0% b.i.d. [upper limit of 95% confidence interval (CI) strictly lower than 1.5 mmHg] was met at 6/9 time points (Day 1: h 8 and 12; Day 28: h 2, 4, 8, and 12). Similar comparative efficacy was seen for the other H-1337 treatment groups. The most common adverse event observed was hyperemia, reported in 54.0% (27/50) for H-1337 1.0% q.d., 33.3% (17/51) for H-1337 0.6% b.i.d., 41.2% (21/51) for H-1337 1.0% b.i.d., and 8.2% (4/49) for timolol.
CONCLUSION: H-1337 in doses of 0.6% b.i.d., 1.0% q.d., and 1.0% b.i.d. had ocular hypotensive efficacy in the range of timolol, although not within the strict Phase 3 non-inferiority margins, which would have required a larger sample size.
DESIGN: Phase 2B, randomized, double-masked, active-controlled, dose-response study of 28 days of four treatments: H-1337 0.6% b.i.d., 1.0% b.i.d., or 1.0% q.d. (1.0% in the morning with H-1337 vehicle in the evening), and timolol maleate 0.5% b.i.d.
PARTICIPANTS: Two hundred one subjects with open-angle glaucoma or ocular hypertension at eight private practice sites in the United States.
METHODS: Diurnal intraocular pressure (IOP) over 28 days of dosing.
MAIN OUTCOME MEASURES: Non-inferiority to timolol in change from baseline in IOP at Day 1 and Day 28.
RESULTS: Mean reduction in IOP was 4-7 mmHg for the H-1337 groups and 5-8 mmHg for the timolol group. Non-inferiority to timolol for H-1337 1.0% b.i.d. [upper limit of 95% confidence interval (CI) strictly lower than 1.5 mmHg] was met at 6/9 time points (Day 1: h 8 and 12; Day 28: h 2, 4, 8, and 12). Similar comparative efficacy was seen for the other H-1337 treatment groups. The most common adverse event observed was hyperemia, reported in 54.0% (27/50) for H-1337 1.0% q.d., 33.3% (17/51) for H-1337 0.6% b.i.d., 41.2% (21/51) for H-1337 1.0% b.i.d., and 8.2% (4/49) for timolol.
CONCLUSION: H-1337 in doses of 0.6% b.i.d., 1.0% q.d., and 1.0% b.i.d. had ocular hypotensive efficacy in the range of timolol, although not within the strict Phase 3 non-inferiority margins, which would have required a larger sample size.